Radiopharm Theranostics reported interim Phase IIb imaging results showing RAD‑101 (F18‑Pivalate) met its primary endpoint, achieving concordance with MRI in 92% of treated brain metastasis patients, company and trial summaries stated. The 11‑of‑12 patient concordance signals selective tumor uptake and metabolic activity by PET that aligned with clinical imaging expectations. The readout supports continued development of RAD‑101 as a diagnostic adjunct for brain metastases detection and assessment. Trial investigators noted the tracer’s potential to resolve equivocal MRI findings and to provide metabolic information that could guide treatment planning. Pending full dataset publication, sponsors plan to discuss regulatory pathway options for diagnostic claims and potential companion roles with therapeutic radiosurgery or systemic regimens.